Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. New in 2013, HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.
Complete HGT Program coverage includes:
- Improvements in vector developments
- Delivery systems
- Cell therapy
- Small nucleic acid therapeutics, including RNAi
- Clinical trials and animal models
- Clinical protocols
- Pre-clinical animal and in vitro studies to assess the safety of gene and cell therapy products used to support clinical applications
- Clinical trials including those in which the results are confirmatory or negative
- Topical issues related to the commercial development of gene and cell therapy products
Human Gene Therapy was voted one of the most influential journals in Biology and Medicine over the last 100 years by the Biomedical & Life Sciences Division of the Special Libraries Association.
Human Gene Therapy, HGT Methods, and HGT Clinical Development are under the editorial leadership of Editor-in-Chief James M. Wilson, MD, PhD, University of Pennsylvania School of Medicine, Gene Therapy Program, Department of Pathology and Laboratory Medicine; Deputy Editor Professor George Dickson, Institute of Biomedical & Life Sciences, School of Biological Sciences, University of London; Human Gene Therapy Editor Mark A. Kay, MD, PhD, Division of Human Gene Therapy, Departments of Pediatrics and Genetics, Stanford University School of Medicine; Methods Editor Thierry VandenDriessche, PhD, Free University of Brussels (VUB); Clinical Development Editor Barry J. Byrne, MD, PhD, Powell Gene Therapy Center, University of Florida, College of Medicine, and other leading investigators. View the entire editorial board.
Audience: Geneticists, medical geneticists, biological scientists, microbiologists, molecular biologists, virologists, experimental researchers, and experimental medicine specialists, among others.
Human Gene Therapy and HGT Methods provide “Instant Online” publication 72 hours after acceptance
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.